GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:16 2024-06-13 am EDT 5-day change 1st Jan Change
1,610 GBX +0.31% Intraday chart for GSK plc -1.83% +11.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
REGENXBIO Inc. Announces Chief Executive Officer Changes CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says MT
GSK: licensing agreement with Ochre Bio CF
Health Care Down as Rally Pauses -- Health Care Roundup DJ
British Shares Extend Stay in Red Amid Signs of Job Market Cooling MT
Global markets live: GSK, Tesla, Intel, General Motors, Gamestop... Our Logo
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing MT
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit MT
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation MT
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim -- Update DJ
GSK takes first steps to appeal Zantac ruling in Delaware AN
FTSE 100 up; UK unemployment rises to 4.4% AN
GSK: decisions in the Zantac (ranitidine) litigation CF
FTSE 100 called up despite unemployment rise AN
GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation MT
UK Stocks-Factors to watch on June 11 RE
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim DJ
GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation RE
GSK Sees Dismissal of US Zantac Case Without Settlement MT
Latest trial over Zantac cancer claims called off as plaintiff drops case RE
GSK welcomes dismissal of Zantac case in Illinois AN
Gsk PLC - Statement Zantac (Ranitidine) Litigation RE
GSK Says FDA Approved RSV Vaccine's Expanded Age Indication MT
Moderna COVID/flu combo vaccine superior to separate shots in trial RE
GSK plc Announces That the US Food and Drug Administration Has Approved Arexvy CI
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.05 GBP
Average target price
20.36 GBP
Spread / Average Target
+26.88%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK's Zantac Cleared in Chicago Jury Trial for Alleged Colon Cancer Link